Caplin Point Laboratories Crecimiento futuro

Future controles de criterios 2/6

Se prevé un crecimiento anual de los beneficios y los ingresos de Caplin Point Laboratories de 1% y 12.5% por año respectivamente. Se prevé que el BPA crezca en un 10.9% al año. Se espera que la rentabilidad financiera sea de 15% en 3 años.

Información clave

11.7%

Tasa de crecimiento de los beneficios

11.8%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Pharmaceuticals	17.1%
Tasa de crecimiento de los ingresos	12.8%
Rentabilidad financiera futura	17.8%
Cobertura de analistas	Low
Última actualización	06 Jun 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Caplin Point Laboratories (NSE:CAPLIPOINT) Strong Profits May Be Masking Some Underlying Issues

May 24

Does Caplin Point Laboratories (NSE:CAPLIPOINT) Deserve A Spot On Your Watchlist?

May 04

Caplin Point Laboratories Limited's (NSE:CAPLIPOINT) Low P/E No Reason For Excitement

Mar 07

With EPS Growth And More, Caplin Point Laboratories (NSE:CAPLIPOINT) Makes An Interesting Case

Oct 24

Why We Think The CEO Of Caplin Point Laboratories Limited (NSE:CAPLIPOINT) May Soon See A Pay Rise

Sep 15

Caplin Point Laboratories (NSE:CAPLIPOINT) Will Pay A Larger Dividend Than Last Year At ₹2.50

Aug 11

We Discuss Whether Caplin Point Laboratories Limited's (NSE:CAPLIPOINT) CEO Is Due For A Pay Rise

Sep 23

Caplin Point Laboratories' (NSE:CAPLIPOINT) Shareholders Will Receive A Bigger Dividend Than Last Year

Sep 11

Is Now The Time To Put Caplin Point Laboratories (NSE:CAPLIPOINT) On Your Watchlist?

Jul 22

Caplin Point Laboratories (NSE:CAPLIPOINT) Is Increasing Its Dividend To ₹2.00

May 15

A Look At The Intrinsic Value Of Caplin Point Laboratories Limited (NSE:CAPLIPOINT)

Jan 21

Should You Be Adding Caplin Point Laboratories (NSE:CAPLIPOINT) To Your Watchlist Today?

Oct 20

Caplin Point Laboratories (NSE:CAPLIPOINT) Is Increasing Its Dividend To ₹1.50

Sep 17

Caplin Point Laboratories (NSE:CAPLIPOINT) Will Pay A Larger Dividend Than Last Year At ₹1.50

Sep 03

Caplin Point Laboratories Limited's (NSE:CAPLIPOINT) Intrinsic Value Is Potentially 28% Above Its Share Price

Aug 27

Is Caplin Point Laboratories (NSE:CAPLIPOINT) A Risky Investment?

Jun 12

Estimating The Fair Value Of Caplin Point Laboratories Limited (NSE:CAPLIPOINT)

Apr 29

Does Caplin Point Laboratories Limited (NSE:CAPLIPOINT) Have A Place In Your Dividend Portfolio?

Mar 24

We Think Caplin Point Laboratories (NSE:CAPLIPOINT) Can Stay On Top Of Its Debt

Mar 11

Do Caplin Point Laboratories's (NSE:CAPLIPOINT) Earnings Warrant Your Attention?

Feb 26

What We Learned About Caplin Point Laboratories' (NSE:CAPLIPOINT) CEO Pay

Feb 14

Caplin Point Laboratories Limited's (NSE:CAPLIPOINT) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?

Feb 02

Can You Imagine How Jubilant Caplin Point Laboratories' (NSE:CAPLIPOINT) Shareholders Feel About Its 105% Share Price Gain?

Jan 21

Does This Valuation Of Caplin Point Laboratories Limited (NSE:CAPLIPOINT) Imply Investors Are Overpaying?

Jan 09

Could The Caplin Point Laboratories Limited (NSE:CAPLIPOINT) Ownership Structure Tell Us Something Useful?

Dec 28

Is It Worth Buying Caplin Point Laboratories Limited (NSE:CAPLIPOINT) For Its 0.5% Dividend Yield?

Dec 16

We Think Caplin Point Laboratories (NSE:CAPLIPOINT) Can Stay On Top Of Its Debt

Dec 04

Should You Be Adding Caplin Point Laboratories (NSE:CAPLIPOINT) To Your Watchlist Today?

Nov 21

Here's What We Learned About The CEO Pay At Caplin Point Laboratories Limited (NSE:CAPLIPOINT)

Nov 08

Previsiones de crecimiento de beneficios e ingresos

NSEI:CAPLIPOINT - Estimaciones futuras de los analistas y datos financieros pasados (INR Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
3/31/2027	25,271	6,873	4,911	5,035	1
3/31/2026	22,140	5,618	3,983	4,586	3
3/31/2025	19,670	5,226	3,277	3,554	2
3/31/2024	16,941	4,571	1,726	3,184	N/A
12/31/2023	16,318	4,376	N/A	N/A	N/A
9/30/2023	15,683	4,179	399	2,593	N/A
6/30/2023	15,157	3,947	N/A	N/A	N/A
3/31/2023	14,683	3,763	779	2,714	N/A
12/31/2022	14,182	3,532	N/A	N/A	N/A
9/30/2022	13,724	3,307	2,305	3,467	N/A
6/30/2022	13,153	3,140	N/A	N/A	N/A
3/31/2022	12,710	2,998	2,456	3,367	N/A
12/31/2021	12,099	2,872	N/A	N/A	N/A
9/30/2021	11,581	2,767	1,288	2,044	N/A
6/30/2021	11,217	2,586	N/A	N/A	N/A
3/31/2021	10,624	2,423	1,953	2,686	N/A
12/31/2020	9,986	2,248	N/A	N/A	N/A
9/30/2020	9,524	2,189	1,650	1,877	N/A
6/30/2020	9,107	2,193	N/A	N/A	N/A
3/31/2020	8,640	2,150	-321	447	N/A
12/31/2019	8,356	2,159	N/A	N/A	N/A
9/30/2019	7,664	2,032	-331	830	N/A
6/30/2019	6,948	1,894	N/A	N/A	N/A
3/31/2019	6,490	1,766	182	834	N/A
12/31/2018	6,048	1,621	N/A	N/A	N/A
9/30/2018	5,874	1,538	N/A	N/A	N/A
6/30/2018	5,628	1,459	N/A	N/A	N/A
3/31/2018	5,399	1,448	180	665	N/A
12/31/2017	5,145	1,430	N/A	N/A	N/A
9/30/2017	4,757	1,297	N/A	N/A	N/A
6/30/2017	4,401	1,165	N/A	N/A	N/A
3/31/2017	4,016	956	N/A	676	N/A
12/31/2016	3,655	783	N/A	N/A	N/A
9/30/2016	3,420	703	N/A	N/A	N/A
6/30/2016	3,238	619	N/A	N/A	N/A
3/31/2016	3,088	584	N/A	565	N/A
12/31/2015	2,906	535	N/A	N/A	N/A
9/30/2015	2,722	465	N/A	N/A	N/A
6/30/2015	2,518	410	N/A	499	N/A
3/31/2015	2,296	353	N/A	N/A	N/A
12/31/2014	2,074	318	N/A	N/A	N/A
9/30/2014	1,893	305	N/A	N/A	N/A
6/30/2014	1,731	258	N/A	598	N/A
3/31/2014	1,643	204	N/A	N/A	N/A
12/31/2013	1,517	167	N/A	N/A	N/A
9/30/2013	1,408	125	N/A	N/A	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: El pronóstico de crecimiento de los beneficios (11.6% al año) de CAPLIPOINT es superior a la tasa de ahorro (6.7%).

Beneficios vs. Mercado: Se prevé que los beneficios (1% al año) de CAPLIPOINT crezcan menos que el mercado Indian (17.8% al año).

Beneficios de alto crecimiento: Se prevé que los beneficios de CAPLIPOINT crezcan, pero no significativamente.

Ingresos vs. Mercado: Se prevé que los ingresos (12.5% al año) de CAPLIPOINT crezcan más rápidamente que los del mercado Indian (10.3% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos 12.5% al año) de CAPLIPOINT crezcan más despacio que 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Se prevé que la rentabilidad financiera de CAPLIPOINT sea baja dentro de 3 años (15%).

Caplin Point Laboratories Crecimiento futuro

Future controles de criterios 2/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Price target increased by 8.0% to ₹1,076

Price target increased to ₹948

Recent updates

Caplin Point Laboratories Limited Appoints Thiagaraja Manikandan as Chief Transformation & Digital Officer

Investor sentiment improves as stock rises 18%

Caplin Point Laboratories (NSE:CAPLIPOINT) Strong Profits May Be Masking Some Underlying Issues

Full year 2024 earnings: Revenues in line with analyst expectations

Caplin Point Laboratories Limited Declares an Interim Dividend for the Financial Year Ended March 31, 2024

Caplin Point Laboratories Limited to Report Fiscal Year 2024 Results on May 16, 2024

Does Caplin Point Laboratories (NSE:CAPLIPOINT) Deserve A Spot On Your Watchlist?

Caplin Point Laboratories Limited's (NSE:CAPLIPOINT) Low P/E No Reason For Excitement

Third quarter 2024 earnings released: EPS: ₹15.44 (vs ₹12.86 in 3Q 2023)

Caplin Point Laboratories Limited to Report Q3, 2024 Results on Feb 09, 2024

Investor sentiment improves as stock rises 16%

Price target increased by 8.0% to ₹1,076

Second quarter 2024 earnings released: EPS: ₹15.13 (vs ₹12.09 in 2Q 2023)

Caplin Point Laboratories Limited to Report Q2, 2024 Results on Nov 09, 2023

With EPS Growth And More, Caplin Point Laboratories (NSE:CAPLIPOINT) Makes An Interesting Case

Caplin Point Laboratories Limited Approves Final Dividend for the Year Ended March 31, 2023

Why We Think The CEO Of Caplin Point Laboratories Limited (NSE:CAPLIPOINT) May Soon See A Pay Rise

Upcoming dividend of ₹2.50 per share at 0.5% yield

Caplin Point Laboratories Limited, Annual General Meeting, Sep 21, 2023

Investor sentiment improves as stock rises 15%

Caplin Point Laboratories (NSE:CAPLIPOINT) Will Pay A Larger Dividend Than Last Year At ₹2.50

Caplin Point Laboratories Limited Recommends Final Dividend for the Financial Year Ended March 31, 2023

First quarter 2024 earnings released: EPS: ₹13.62 (vs ₹11.21 in 1Q 2023)

Caplin Point Laboratories Limited to Report Q1, 2024 Results on Aug 07, 2023

Caplin Steriles Limited Gets United States Food and Drug Administration Approval for Cisatracurium Besylate Injection USP

Upcoming dividend of ₹2.00 per share at 0.3% yield

Full year 2023 earnings: EPS exceeds analyst expectations

Caplin Point Laboratories Limited to Report Q4, 2023 Results on May 24, 2023

Now 20% undervalued after recent price drop

Third quarter 2023 earnings released: EPS: ₹12.86 (vs ₹9.90 in 3Q 2022)

Caplin Point Laboratories Limited to Report Q3, 2023 Results on Feb 11, 2023

Price target increased to ₹948

Caplin Point Laboratories Limited (BSE:524742) acquired API plant in Vizag from Metrochem API Private Limited.

Second quarter 2023 earnings released: EPS: ₹12.09 (vs ₹9.91 in 2Q 2022)

Caplin Point Laboratories Limited to Report Q2, 2023 Results on Nov 12, 2022

Caplin Point Laboratories Limited Approves Final Dividend for the Financial Year Ended March 31, 2022

Caplin Point Laboratories Limited Announces Change in Directorate

We Discuss Whether Caplin Point Laboratories Limited's (NSE:CAPLIPOINT) CEO Is Due For A Pay Rise

Upcoming dividend of ₹2.00 per share

Caplin Point Laboratories' (NSE:CAPLIPOINT) Shareholders Will Receive A Bigger Dividend Than Last Year

Caplin Point Laboratories Limited, Annual General Meeting, Sep 29, 2022

Caplin Point Laboratories Limited, Annual General Meeting, Sep 29, 2022

Caplin Point Laboratories Limited Recommends Final Dividend for the Financial Year Ended March 31, 2022

First quarter 2023 earnings released: EPS: ₹11.21 (vs ₹9.37 in 1Q 2022)

Caplin Point Laboratories Limited to Report Q1, 2023 Results on Aug 05, 2022

Is Now The Time To Put Caplin Point Laboratories (NSE:CAPLIPOINT) On Your Watchlist?

Caplin Point Laboratories Limited Announces Resignation of D P Mishra as Non-Executive, Non-Independent Director

Investor sentiment improved over the past week

Upcoming dividend of ₹2.00 per share

Full year 2022 earnings: Revenues and EPS in line with analyst expectations

Caplin Point Laboratories (NSE:CAPLIPOINT) Is Increasing Its Dividend To ₹2.00

Caplin Point Laboratories Limited Approves Interim Dividend for the Financial Year Ended March 31, 2022

Caplin Point Laboratories Limited to Report Fiscal Year 2022 Results on May 12, 2022

Insufficient new directors

Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Caplin Point Laboratories Limited to Report Q3, 2022 Results on Feb 03, 2022

A Look At The Intrinsic Value Of Caplin Point Laboratories Limited (NSE:CAPLIPOINT)

Insufficient new directors

Insider recently sold ₹4.3m worth of stock

Second quarter 2022 earnings released: EPS ₹9.91 (vs ₹7.52 in 2Q 2021)

Should You Be Adding Caplin Point Laboratories (NSE:CAPLIPOINT) To Your Watchlist Today?

Caplin Point Laboratories (NSE:CAPLIPOINT) Is Increasing Its Dividend To ₹1.50

Upcoming dividend of ₹1.50 per share

Investor sentiment improved over the past week

Caplin Point Laboratories (NSE:CAPLIPOINT) Will Pay A Larger Dividend Than Last Year At ₹1.50

Caplin Point Laboratories Limited's (NSE:CAPLIPOINT) Intrinsic Value Is Potentially 28% Above Its Share Price

First quarter 2022 earnings released: EPS ₹9.37 (vs ₹7.21 in 1Q 2021)

Investor sentiment improved over the past week

Is Caplin Point Laboratories (NSE:CAPLIPOINT) A Risky Investment?

Non-Executive Independent Director has left the company

Upcoming dividend of ₹1.50 per share

Full year 2021 earnings released: EPS ₹32.03 (vs ₹28.42 in FY 2020)

Caplin Point Laboratories Limited Declares Interim Dividend for the Financial Year Ended March 31, 2021